The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Eunice WangDuring the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked: Why could IMGN632, a novel CD123-targeting antibody-drug conjugate, be an important treatment option for acute myeloid leukemia?
Eunice Wang discusses the results from the phase Ib study that explored the potent IMGN632 antibody-drug conjugate in patients with AML. She discusses the toxicity and safety profile of the agent and states the recommended dose. She also talks about the efficacy of this antibody-drug conjugate in the high-risk patient population.
Why could IMGN632 be an important treatment option for AML?